RE-BVS – Piemonte Repository

Sfoglia per AUTORE
VIGNETTI M
Collezione AOU Alessandria

Items : 4

Health-related quality of life and symptom profile of patients with BCR::ABL1-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational study. in HemaSphere / Hemasphere. 2025 Dec 28;9(12):e70274. doi: 10.1002/hem3.70274. eCollection 2025 Dec.

2025
AOU Alessandria

Caocci G; Costa A; Palandri F; Guglielmelli P; Patriarca A; Iurlo A; Tieghi A; Abruzzese E; Baldi T; Rossi E; Beggiato E; Marchetti M; Fava C; Tomassetti S; Rumi E; Fozza C; Luppi M; Pane F; Bigliardi S; Breccia M; Elli EM; Tartaglia F; Mulas O; Fazi P; Vignetti M; Vannucchi AM; Efficace F;

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Foà R; Nanni M; Del Giudice I; Guarini A; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Neri A; De Novi LA; De Propris MS; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Molinari MC; Liberati AM; Giordano A; Gottardi D; Galieni P; Patrizi VB; Tani M; Arcari A; Musuraca G; Deodato M; Massaia M; Rigolin GM; Scarfò L; et alii...

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. in Blood / Blood. 2021 Dec 23;138(25):2727-2730. doi: 10.1182/blood.2021011883.

2021
AOU Alessandria

Rigolin GM; Del Giudice I; Bardi A; Melandri A; García-Jacobo RE; Cura F; Raponi S; Ilari C; Cafforio L; Piciocchi A; Arena V; Reda G; Albano F; Molica S; Sportoletti P; Trentin L; Marchetti M; Nanni M; Peragine N; Mariglia P; Vignetti M; Guarini A; Mauro FR; Foà R; Cuneo A;

High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). in Haematologica / Haematologica. 2020 Nov 1;105(11):2671-2674. doi: 10.3324/haematol.2019.235705.

2020
AOU Alessandria
AOU Città della Salute di Torino

Della Starza I; Del Giudice I; Cuneo A; Albano F; Neri A; Vignetti M; Piciocchi A; Nanni M; Musolino C; Del Poeta G; Battistini R; Gozzetti A; Pietrasanta D; Reda G; Tedeschi A; Liberati AM; Re F; Angelucci E; Zaja F; Coscia M; Ilariucci F; Soddu S; Molica S; Mauro FR; De Propris MS; Raponi S; Guarini AR; Foà R;